Rob Scott, Chief Medical Officer at AbbVie, discusses the importance of a clinician’s perspective for keeping clinical trial development focussed on the patients. Rob talks about how the role of a Chief Medical Officer changes between a large pharma company and small biotechs. He then covers the key areas in which new developments in healthcare technology can help us better understand a patient’s response to therapies and interventions.